Karen Mcclorey Hackett is a journalist who writes for the Precision Vaccines Program. Her work focuses on providing updates and analysis on vaccine-related topics, including vaccine development, disease outbreaks, and public health initiatives. Her articles have also been featured in Vax-Before-Travel, a publication dedicated to vaccine news and information.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Karen Mcclorey Hackett's coverage heavily revolves around public health, vaccines, disease outbreaks, and clinical trials. She consistently cites data and government announcements in her articles. To effectively reach out to her, consider providing access to reliable and up-to-date data related to public health issues or breakthroughs in vaccine development.
Experts with a deep understanding of global health trends, clinical trial outcomes, or experience working on the front lines of disease prevention would likely capture Karen’s interest given the nature of her reporting. It is important to note that she does not have a specific geographic focus but rather covers global healthcare topics comprehensively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Karen Mcclorey Hackett
MenB vaccination reduces gonorrhea infections
By: Karen Mcclorey Hackett
When searching for a winter holiday destination in 2024, Bermuda may top the healthy destination list, as no vaccination requirements are currently in effect. This good news helped boost Bermuda's tourism industry in 2023 when arrivals (air, cruise, and yacht) increased by 29.1% year over year. As of November 18, 2024, this British Overseas Territory, which is home to about 63,000 people and is located in the middle of the Atlantic Ocean, has the lowest travel advisory status with the U.S. and U.K. governments.
By: Karen Mcclorey Hackett
High priority pathogens require protective vaccines
By: Karen Mcclorey Hackett
Oropouche outbreaks 3.9 times greater in small municipalities
The World Health Organization (WHO) today announced it has granted Emergency Use Listing (EUL) for the LC16m8 smallpox / mpox vaccine, making it the second mpox vaccine to be supported by WHO. LC16m8 is a vaccine developed and manufactured by KM Biologics in Japan. It is recommended by the WHO for use in individuals over one year of age as a single-dose vaccine via a multiple puncture technique using a bifurcated needle.
By: Karen Mcclorey Hackett
The U.K. Health Security Agency says the timing of the typical norovirus seasonal increase and peak of activity varies from season to season. This season, the increase in reporting has begun earlier than in the last five seasons.
By: Karen Mcclorey Hackett
Dyadic International, Inc. announced today that it has been awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV) and malaria utilizing the company's proprietary C1 protein production platform to provide globally accessible treatment options for underserved populations.
Cholera vaccine supply improves in 2024
By: Karen Mcclorey Hackett
Chikungunya vaccine available in 2024
By: Karen Mcclorey Hackett
Shigellosis vaccine Candidate Granted FDA Fast Track designation
(833) 317-6278 
